

#### 招商银行全资附属机本 A Wholly Owned Subsidiary Of China Merchants Ban

# GAC Group (2238 HK)

# Aion's turning profitable as a positive catalyst

**Maintain BUY.** GAC's 3Q23 earnings beat, as Aion turned profitable, which could be a positive catalyst. Equity income from JVs was also more resilient than expected. We project GAC's FY24E NP to rise 31% YoY to RMB 6.1bn.

- 3Q23 earnings beat. GAC's 3Q23 revenue was 2% lower than our prior forecast while its GPM widened by 4.1 ppts QoQ and beat our projection by 3 ppts. Management attributed such increase to lowered battery price and better product mix from the *Hyper GT*. Excluding GAC Mitsubishi's goodwill impairment, GAC's equity income in 3Q23 rose slightly QoQ, which also beat our forecast. Accordingly, GAC's NP in 3Q23 was about RMB 200mn higher than our prior forecast, despite higher-than-expected impairment.
- Aion turned profitable in 3Q23, which could attract more investors. Aion turned profitable in 3Q23, sooner than our prior forecast, underscoring our previous argument of 'a better FY24E ahead'. Despite uncertainties from rising competition and raw-material price volatility, we expect Aion to be close to break even in FY24E. We maintain our sales volume forecast of 0.57mn units for Aion in FY24E but lower its average selling price by 12% to reflect heightened competition and slower-than-expected Hyper ramp-up. We expect GAC's net loss excluding equity income to narrow by RMB 1bn YoY in FY24E.
- We still take a conservative approach for JVs despite their resilient earnings in 3Q23. We view GAC Mitsubishi's restructuring as neutral given GAC's capital injection and PP&E purchases. Although we expect GAC's equity income to rise YoY in FY24E, as GAC Mitsubishi's overhang is to be gone, we lower FY24E equity income by RMB 400mn to RMB 8.1bn, as we are concerned about GAC Honda's earnings outlook.
- Earnings/Valuation. We only lower our FY23E NP by 5% despite costs for GAC Mitsubishi's restructuring costs, given the 3Q23 earnings beat. We raise FY24E NP by 4% to reflect Aion's improving earnings outlook. We use sum-of-the-parts (SOTP) valuation to factor in Aion's planned spin-off. We value Aion HK\$ 4.0 (prior HK\$4.4) per share, based on 0.7x (unchanged) our revised FY24E P/S. We value HK\$ 2.5 (prior HK\$ 2.6) per share for JVs and associates based on 3.0x (unchanged) our FY24E P/E. We value 0 for all other businesses combined. We maintain BUY rating but lower target price from HK\$ 7.00 to 6.50. Key risks to our rating and target price include lower sales volume and margins especially for Aion and a sector de-rating.

# **Earnings Summary**

(YE 31 Dec)	FY21A	FY22A	FY23E	FY24E	FY25E
Revenue (RMB mn)	75,676	110,006	140,545	141,158	148,344
YoY growth (%)	19.8	45.4	27.8	0.4	5.1
Net income (RMB mn)	7,511	7,983	4,670	6,117	6,031
EPS (RMB)	0.73	0.77	0.44	0.58	0.57
YoY growth (%)	25.9	6.3	(41.5)	31.0	(1.4)
P/E (x)	4.1	4.1	7.6	5.9	5.9
P/B (x)	0.3	0.3	0.3	0.3	0.3
Yield (%)	3.6	4.2	2.3	3.0	2.9
ROE (%)	8.6	7.8	4.1	5.1	4.9
Net gearing (%)	Net cash				

Source: Company data, Bloomberg, CMBIGM estimates

# **BUY (Maintain)**

Target Price HK\$ 6.50 (Previous TP HK\$ 7.00) Up/Downside +78.6% Current Price HK\$ 3.64

#### **China Auto Sector**

**SHI Ji, CFA** (852) 3761 8728 shiji@cmbi.com.hk

DOU Wenjing, CFA (852) 6939 4751 douwenjing@cmbi.com.hk

**GU Sijie** jasongu@cmbi.com.hk

Stock Data	
Mkt Cap (HK\$ mn)	38,170
Avg 3 mths t/o (HK\$ mn)	58
52w High/Low (HK\$)	5.98/3.57
Total Issued Shares (mn)	10,485

Shareholding Structure

Guangzhou Automobile
Industry
Others 47.5%

Source: HKEx

# Share Performance Absolute Relative 1-mth -3.2% -0.8% 3-mth -19.6% -7.7% 6-mth -19.8% -6.1%

Source: Bloomberg

Source: Bloombera

# 12-mth Price Performance (HK\$) —— 2238 HK —— HSI (rebased) 8.0 7.0 6.0 5.0 4.0 3.0 2.0 1.0 0.0 2022-10 2023-01 2023-04 2023-07 2023-10

**Related Reports** 

Source: Bloomberg

"GAC Group – Homegrown brands likely to narrow loss in 2H23" – 28 Aug 2023

Auditor: PricewaterhouseCoopers



Figure 1: Quarterly results

RMB mn	1Q22	2Q22	3Q22	4Q22	1Q23	2Q23	3Q23	YoY	QoQ
Sales volume (units)	608,167	541,759	675,024	608,761	539,875	623,029	629,559	-6.7%	1.0%
Revenue	23,268	25,421	31,678	29,639	26,557	35,354	36,271	14.5%	2.6%
Gross profit	1,025	1,160	1,470	2,320	610	1,458	2,963	101.6%	103.2%
R&D expenses	(241)	(319)	(388)	(760)	(397)	(464)	(450)	16.1%	-3.0%
SG&A expenses	(2,110)	(2,287)	(2,324)	(1,676)	(1,883)	(2,528)	(2,809)	20.9%	11.1%
Investment Income	4,227	4,271	3,770	2,049	2,955	2,494	1,833	-51.4%	-26.5%
Operating profit	2,854	2,883	2,102	(383)	1,145	1,241	1,480	-29.6%	19.3%
Net profit	3,009	2,742	2,312	6	1,538	1,428	1,545	-33.2%	8.1%
Gross margin	4.4%	4.6%	4.6%	7.8%	2.3%	4.1%	8.2%	3.5 ppt	4.0 ppt
Operating margin	12.3%	11.3%	6.6%	-1.3%	4.3%	3.5%	4.1%	-2.6 ppt	0.6 ppt
Net margin	12.9%	10.8%	7.3%	0.0%	5.8%	4.0%	4.3%	-3.0 ppt	0.2 ppt

Source: Company data, CMBIGM

Figure 2: Earnings revision

		New			Old		Diff (%)		
RMB mn	FY23E	FY24E	FY25E	FY23E	FY24E	FY25E	FY23E	FY24E	FY25E
Revenue	140,545	141,158	148,344	142,585	156,375	170,166	-1.4%	-9.7%	-12.8%
Gross profit	7,503	9,270	11,988	6,242	8,509	13,603	20.2%	8.9%	-11.9%
Operating profit	(3,899)	(2,288)	(482)	(5,666)	(3,135)	592	N/A	N/A	N/A
Net profit	4,670	6,117	6,031	4,924	5,907	7,593	-5.2%	3.5%	-20.6%
Gross margin	5.3%	6.6%	8.1%	4.4%	5.4%	8.0%	1.0 ppt	1.1 ppt	0.1 ppt
Operating margin	-2.8%	-1.6%	-0.3%	-4.0%	-2.0%	0.3%	1.2 ppt	0.4 ppt	-0.7 ppt
Net margin	3.3%	4.3%	4.1%	3.5%	3.8%	4.5%	-0.1 ppt	0.6 ppt	-0.4 ppt

Source: CMBIGM estimates

Figure 3: CMBI estimates vs consensus

		CMBIGM			Consensus	;	Diff (%)			
RMB mn	FY23E	FY24E	FY25E	FY23E	FY24E	FY25E	FY23E	FY24E	FY25E	
Revenue	140,545	141,158	148,344	137,195	158,268	176,863	2.4%	-10.8%	-16.1%	
Gross profit	7,503	9,270	11,988	7,480	10,172	13,127	0.3%	-8.9%	-8.7%	
Operating profit	(3,899)	(2,288)	(482)	(5,469)	(4,571)	(1,118)	N/A	N/A	N/A	
Net profit	4,670	6,117	6,031	6,911	7,564	8,326	-32.4%	-19.1%	-27.6%	
Gross margin	5.3%	6.6%	8.1%	5.5%	6.4%	7.4%	-0.1 ppt	0.1 ppt	0.7 ppt	
Operating margin	-2.8%	-1.6%	-0.3%	-4.0%	-2.9%	-0.6%	1.2 ppt	1.3 ppt	0.3 ppt	
Net margin	3.3%	4.3%	4.1%	5.0%	4.8%	4.7%	-1.7 ppt	-0.4 ppt	-0.6 ppt	

Source: Bloomberg, CMBIGM estimates

Figure 4: SOTP valuation

GAC (2238 HK)	FY24E (RMB bn)	Target P/E Multiple	Target P/S Multiple	Est. Shareholding	Target Market Cap (HK\$ bn)	Target Price (HK\$)
Estimated Revenue of Aion	70.3	-	0.7x	77%	40.9	4.0
Estimated Share of Profits of Joint Ventures & Associates	8.1	3.0x	-	-	26.1	2.5
SOTP					66.4	6.5

Source: CMBIGM estimates



# **Financial Summary**

Income statement						Cash flow					
YE 31 Dec (RMB mn)	FY21A	FY22A	FY23E	FY24E	FY25E	YE 31 Dec (RMB mn)	FY21A	FY22A	FY23E	FY24E	FY25E
Revenue	75,676	110,006	140,545	141,158	148,344	Profit before taxation	7,412	7,377	4,003	5,944	6,289
Cost of sales	(71,777)	(105,550)	(133,042)	(131,887)	(136,356)	Depreciation/amortization	5,719	6,690	7,547	8,500	9,467
Gross profit	3,899	4,457	7,503	9,270	11,988	Change in working capital	(8,134)	(9,458)	(2,620)	943	(1,193)
						Others	(11,488)	(11,246)	(6,341)	(6,570)	(5,387)
Selling exp.	(4,340)	(4,228)	(5,866)	(5,249)	(5,650)	Net cash from operating	(6,491)	(6,638)	2,589	8,818	9,176
Admin exp.	(4,556)	(5,487)	(6,186)	(6,842)	(7,553)						
Other gains	1,371	(1,409)	650	533	733	Capex	(6,243)	(8,014)	(9,000)	(9,100)	(9,100)
Operating profit	(3,626)	(6,668)	(3,899)	(2,288)	(482)	Others	13,478	6,421	6,905	6,241	4,160
						Net cash from investing	7,235	(1,592)	(2,095)	(2,859)	(4,940)
Net finance costs	(367)	(21)	239	169	184	•	•			, , ,	, ,
Profit share of asso.&JVs	11,404	14,065	7,663	8,063	6,587	Net borrowings	2,657	6,200	(6,466)	(1,061	(2,006)
Pre-tax profit	7,412	7,377	4,003	5,944	6,289	Dividend paid	(2,135)	(2,485)	(2,321)	(1,639)	(1,969)
	-,	.,	-,	-,	-,	Others	255	21,466	(268)	(261)	(254)
Tax	154	536	293	170	30	Net cash from financing	777	25,181	(9,054)	(2,962)	(4,229)
Minority interests	(55)	71	374	3	(287)	not odon nom manomy	• • • • • • • • • • • • • • • • • • • •	20,101	(0,00-1)	(2,002)	(1,220)
Net profit	7,511	7,983	4,670	6,117	6,031	Net change in cash	1,520	16,950	(8,560)	2,997	7
Net prom	7,511	7,303	4,070	0,117	0,031	Cash at year beginning	15,791	17,235	34,222	25,662	28,659
						Exchange difference		37	34,222	25,002	20,009
						Cash at year end	(76) <b>17,235</b>	34,222	25,662	28,659	28,666
						- Cash at year cha	17,200	04,222	20,002	20,000	20,000
Balance sheet						Key ratios					
YE 31 Dec (RMB mn)	FY21A	FY22A	FY23E	FY24E	FY25E	YE 31 Dec	FY21A	FY22A	FY23E	FY24E	FY25E
Current assets	61,192	91,792	98,135	101,198	103,959	Sales mix (%)					
Cash & equivalents	17,235	34,222	25,662	28,659	28,666	Automobile	65.0	71.5	76.3	78.3	79.3
Account receivables	25,110	31,597	44,281	44,474	46,738	Parts and services	32.1	25.2	21.1	18.9	17.9
Inventories	8,111	12,362	14,580	14,453	14,943	Finance and others	2.9	3.2	2.7	2.8	2.8
Other current assets	10,736	13,612	13,612	13,612	13,612						
						Growth (%)					
Non-current assets	93,059	98,283	100,290	102,102	103,637	Revenue	19.8	45.4	27.8	0.4	5.1
PP&E	19,476	20,761	19,645	18,502	17,262	Gross profit	69.8	14.3	68.4	23.6	29.3
Intangibles	13,581	14,471	16,379	17,257	17,451	Operating profit	1.6	83.9	(41.5)	(41.3)	(78.9)
Deferred income tax	2,834	3,715	3,715	3,715	3,715	Net profit	25.9	6.3	(41.5)	31.0	(1.4)
Other non-current assets	57,168	59,335	60,551	62,628	65,208						
Total assets	154,251	190,075	198,425	203,301	207,596	Profit & loss ratio (%)					
						Gross margin	5.2	4.1	5.3	6.6	8.1
Current liabilities	49,133	56,688	63,272	62,878	62,295	Operating margin	(4.8)	(6.1)	(2.8)	(1.6)	(0.3)
Bank borrowings	9,889	13,813	7,777	6,028	,	Net profit margin	9.9	7.3	3.3	4.3	4.1
Account payables	38,490	42,069	54,675	56,007	57,905	r tot prom margin	0.0		0.0		
Tax payable	202	185	185	185	185	Balance sheet ratio					
Other current liabilities	551	622	635	658	683		0.1	0.1	0.1	0.2	0.2
Other current habilities	551	022	000	000	000	Current ratio (x)	1.2	1.6	1.6	1.6	1.7
Non-current liabilities	12,469	11,084	10,075	10,582	11,111	Receivable turnover days	121	105	115	115	115
		-	-	-	•	•					
Bank borrowings	7,527	5,697	4,697	5,197	5,697	Inventory turnover days	41	43	40 150	40 155	40 155
Government Grants	2,196	2,183	2,056	1,947	1,855	Payable turnover days	196	145	150	155	155
Other non-current liabilities	2,747	3,204	3,323	3,438	3,559	Dunfitability (0/)					
Total liabilities	61,602	67,772	73,347	73,460	73,406	Profitability (%)					
		. =				ROE	8.6	7.8	4.1	5.1	4.9
Share capital	10,371	10,487	10,518	10,528	10,528	ROA	5.1	4.6	2.4	3.0	2.9
Reserves	79,943	102,802	105,990		114,967						
Non-controlling interests	2,335	9,014	8,570	8,487	8,694	Per share data (RMB)					
Shareholders' equity	00 040	440.000	440 500	404 050	405 405		0.70		0.44		
Total equity and liabilities	90,313	113,289	116,508	121,353	125,495	EPS	0.73	0.77	0.44	0.58	0.57

Source: Company data, CMBIGM estimates



# **Disclosures & Disclaimers**

# **Analyst Certification**

The research analyst who is primary responsible for the content of this research report, in whole or in part, certifies that with respect to the securities or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about the subject securities or issuer; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific views expressed by that analyst in this report.

Besides, the analyst confirms that neither the analyst nor his/her associates (as defined in the code of conduct issued by The Hong Kong Securities and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue of this report; (2) will deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report; (3) serve as an officer of any of the Hong Kong listed companies covered in this report; and (4) have any financial interests in the Hong Kong listed companies covered in this report.

## **CMBIGM Ratings**

BUY : Stock with potential return of over 15% over next 12 months
HOLD : Stock with potential return of +15% to -10% over next 12 months
SELL : Stock with potential loss of over 10% over next 12 months

NOT RATED : Stock is not rated by CMBIGM

OUTPERFORM : Industry expected to outperform the relevant broad market benchmark over next 12 months

MARKET-PERFORM : Industry expected to perform in-line with the relevant broad market benchmark over next 12 months

UNDERPERFORM : Industry expected to underperform the relevant broad market benchmark over next 12 months

#### CMB International Global Markets Limited

Address: 45/F, Champion Tower, 3 Garden Road, Hong Kong, Tel: (852) 3900 0888 Fax: (852) 3900 0800

CMB International Global Markets Limited ("CMBIGM") is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned subsidiary of China Merchants Bank)

### **Important Disclosures**

There are risks involved in transacting in any securities. The information contained in this report may not be suitable for the purposes of all investors. CMBIGM does not provide individually tailored investment advice. This report has been prepared without regard to the individual investment objectives, financial position or special requirements. Past performance has no indication of future performance, and actual events may differ materially from that which is contained in the report. The value of, and returns from, any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the performance of underlying assets or other variable market factors. CMBIGM recommends that investors should independently evaluate particular investments and strategies, and encourages investors to consult with a professional financial advisor in order to make their own investment decisions.

This report or any information contained herein, have been prepared by the CMBIGM, solely for the purpose of supplying information to the clients of CMBIGM or its affiliate(s) to whom it is distributed. This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in securities or enter into any transaction. Neither CMBIGM nor any of its affiliates, shareholders, agents, consultants, directors, officers or employees shall be liable for any loss, damage or expense whatsoever, whether direct or consequential, incurred in relying on the information contained in this report. Anyone making use of the information contained in this report does so entirely at their own risk.

The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable. CMBIGM has exerted every effort in its capacity to ensure, but not to guarantee, their accuracy, completeness, timeliness or correctness. CMBIGM provides the information, advices and forecasts on an "AS IS" basis. The information and contents are subject to change without notice. CMBIGM may issue other publications having information and/ or conclusions different from this report. These publications reflect different assumption, point-of-view and analytical methods when compiling. CMBIGM may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report.

CMBIGM may have a position, make markets or act as principal or engage in transactions in securities of companies referred to in this report for itself and/or on behalf of its clients from time to time. Investors should assume that CMBIGM does or seeks to have investment banking or other business relationships with the companies in this report. As a result, recipients should be aware that CMBIGM may have a conflict of interest that could affect the objectivity of this report and CMBIGM will not assume any responsibility in respect thereof. This report is for the use of intended recipients only and this publication, may not be reproduced, reprinted, sold, redistributed or published in whole or in part for any purpose without prior written consent of CMBIGM.

Additional information on recommended securities is available upon request.

For recipients of this document in the United Kingdom

This report has been provided only to persons (I) falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended from time to time) ("The Order") or (II) are persons falling within Article 49(2) (a) to (d) ("High Net Worth Companies, Unincorporated Associations, etc...) of the Order, and may not be provided to any other person without the prior written consent of CMBIGM.

# For recipients of this document in the United States

CMBIGM is not a registered broker-dealer in the United States. As a result, CMBIGM is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. The research analyst who is primary responsible for the content of this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA"). The analyst is not subject to applicable restrictions under FINRA Rules intended to ensure that the analyst is not affected by potential conflicts of interest that could bear upon the reliability of the research report. This report is intended for distribution in the United States solely to "major US institutional investors", as defined in Rule 15a-6 under the US, Securities Exchange Act of 1934, as amended, and may not be furnished to any other person in the United States. Each major US institutional investor that receives a copy of this report by its acceptance hereof represents and agrees that it shall not distribute or provide this report to any other person. Any U.S. recipient of this report wishing to effect any transaction to buy or sell securities based on the information provided in this report should do so only through a U.S.-registered broker-dealer.

#### For recipients of this document in Singapore

This report is distributed in Singapore by CMBI (Singapore) Pte. Limited (CMBISG) (Company Regn. No. 201731928D), an Exempt Financial Adviser as defined in the Financial Advisers Act (Cap. 110) of Singapore and regulated by the Monetary Authority of Singapore. CMBISG may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, as defined in the Securities and Futures Act (Cap. 289) of Singapore, CMBISG accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact CMBISG at +65 6350 4400 for matters arising from, or in connection with the report.